LCTX News and Press, BioTime Inc. From 02/29/24

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2023 financial and operating results on Thursday, March 7, 20...

The DOSED Clinical Study Will Evaluate a Novel Delivery Device in Subacute and Chronic Spinal Cord Injury Patients Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ann...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of 13,461,540 of the ...

2024-02-06 09:21:14 ET More on Lineage Cell Therapeutics Lineage Cell Therapeutics: Not Yet Attractive Stem Cell Company Seeking Alpha’s Quant Rating on Lineage Cell Therapeutics Historical earnings data for Lineage Cell Therapeutics Read the full ar...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into a definitive agreement with certain investors for the purchase and sale of 13,461,540 of the ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results showing retinal structure improvements with RG6501( OpRegen ) from a Phase 1/2a clinical study (C...

2024-01-15 03:12:29 ET Summary Lineage Cell Therapeutics develops cell therapies for degenerative diseases, with 5 cell types in active development. The company has treated over 50 patients with no rejections and has seen 5 cases of retinal regeneration on a single administration ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has submitted an Investigational New Drug amendment (INDa) to the U.S. Food and Drug Administrati...

2023-11-09 23:37:06 ET Start Time: 16:30 End Time: 17:12 Lineage Cell Therapeutics, Inc. (LCTX) Q3 2023 Earnings Conference Call November 09, 2023, 16:30 PM ET Company Participants Brian Culley - CEO Jill Howe - CFO Gary Hogge - SVP, Clinical and Medical ...

2023-11-09 16:05:08 ET More on Lineage Cell Therapeutics A Second Look At Lineage Cell Therapeutics Lineage Cell Therapeutics Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Lineage Cell Therapeutics Historical earnings data for Lineage Cell T...